anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Reflux esophagitis has an increasing prevalence and complex and diverse symptoms. Identifying its risk factors is crucial to understanding the etiology, prevention, and management of the disease. The occurrence of reflux esophagitis may be associated with food reactions, Helicobacter pylori (H. pylori) infection, and metabolic syndromes.
AIM: To investigate the risk factors for reflux esophagitis and analyze the effects of immunoglobulin (Ig) G-mediated food intolerance, H. pylori infection, and metabolic syndrome on reflux esophagitis.
METHODS: Outpatients attending the Second Medical Center of the PLA General Hospital between 2017 and 2021 were retrospectively enrolled. The patients' basic information, test results, gastroscopy results, H. pylori test results, and IgG-mediated food intolerance results were collected. Multivariate logistic regression analysis was used to analyze risk factors for reflux esophagitis. Statistical mediation analysis was used to evaluate the effects of IgG-mediated food intolerance and metabolic syndrome on H. pylori infection affecting reflux esophagitis.
RESULTS: A total of 7954 outpatients were included; the prevalence of reflux esophagitis, IgG-mediated food intolerance, H. pylori infection, and metabolic syndrome were 20.84%, 61.77%, 35.91%, and 60.15%, respectively. Multivariate analysis showed that the independent risk factors for reflux esophagitis included IgG-mediated food intolerance (OR = 1.688, 95%CI: 1.497-1.903, P < 0.00001) and metabolic syndrome (OR = 1.165, 95%CI: 1.030-1.317, P = 0.01484), and the independent protective factor for reflux esophagitis was H. pylori infection (OR = 0.400, 95%CI: 0.351-0.456, P < 0.00001). IgG-mediated food intolerance had a partially positive mediating effect on H. pylori infection as it was associated with reduced occurrence of reflux esophagitis (P = 0.0200). Metabolic syndrome had a partially negative mediating effect on H. pylori infection and reduced the occurrence of reflux esophagitis (P = 0.0220).
CONCLUSION: Patients with IgG-mediated food intolerance and metabolic syndrome were at higher risk of developing reflux esophagitis, while patients with H. pylori infection were at lower risk. IgG-mediated food intolerance reduced the risk of reflux esophagitis pathogenesis in patients with H. pylori infection; however, metabolic syndrome increased the risk of patients with H. pylori infection developing reflux esophagitis.
The BASHIR™ .035 Endovascular Catheter (BEC) and the BEC Short Basket .035 (S-B) are devices intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature. The distal infusion segment of the device contains an expandable radial array of conduits with a total of 48 laser drilled orifices used for the delivery of the therapeutic agents at multiple cross-sectional points of the target vessel location. The infusion segment can be expanded and collapsed by the actuator (slider) located on the handle at the proximal end of the device. The infusion line connector is also located on the handle. The difference between the BEC .035 and the BEC S-B.035 is solely in the length of the basket. In its unexpanded state, the basket of the BEC .035 is 12.5cm long and the BEC S-B .035 basket is 10cm long. The choice of device used will be at the physician's discretion based on the patient's anatomy.
PROBLEM TO BE SOLVED: To obtain a preventive or treating pharmaceutical composition, a preventive food and to provide a preventive method for allergy, especially atopic dermatitis, and to obtain a cosmetic composition having improving activity on rough skin. SOLUTION: A preventive or treating pharmaceutical composition and a preventive food for allergy, and a cosmetic composition having rough skin- improving activity each contains one or more kinds selected from the group consisting of Brassica oleracea var. italica, Brassica oleracea var. botrytis, Brassica oleracea var. acephala, Capsella bursa-pastoris, Raphanus sativus, Arabis grabra, Renunculus sceleratus, Chinese mustard, Cardamine regeliana, Barbarea vulgaris var.  Stricta, Nasturtium officinale, Brassica juncea var. integlifolia Kitamura, Brassica juncea, Eutrema wasabi, Wasabia tenuis, Brassica campestis subsp. napus var. akana, Brassica sugukina, Brassica campestis subsp. rapa, Brassica campestis subsp. napus var. nippo-oleifera, Brassica oleracea var. capitata, Spinacia oleracea, Brassica repa var. pervidis, Apium greveslens var. dulce, Petresslium hortense, Lactuca sativa and Malus pumila var. dulcissima.
The invention discloses an externally applied fumigation-washing traditional Chinese medicine for treating sports injury and rheumatism type osteoarthropathy. The traditional Chinese medicine is characterized in that the traditional Chinese medicine formula and preferable proportion are as follows: 50g of radix clematidis preparata, 50g of achyranthes bidentata, 7.44g of sappanwood, 7.44g of caulis trachelospermi, 7.44g of phryma leptostachya, 7.44g of lycopodium clavatum, 5.58g of ground beeltle, 5.58g of crude sichuan aconite root, 5.58g of raw kusnezoff monkshood root, 5.58g of radix angelicae tuhuo, 5.58g of herba taxilli, 5.58g of flos carthami, 5.58g of radix paeoniae rubra, 5.58g of ligusticum chuanxiong, 5.58g of rhizoma corydalis, 5.58g of cortex cinnamomi, 5.58g of fructus chaenomelis lagenariae, 5.58g of gentiana macrophylla, 5.58g of rhizoma seu radix notopterygii, 7.44g of willow twig, and 7.44g of twig of Japanese pagodatree. The above medicines are severely prepared and ground into crude powder, and then filled into bags for use. For the patients suffering from sports injury and rheumatism type osteoarthropathy, the above traditional Chinese medicines are put into a large-sized enamel basin to soak for 30 min with cold water and then heated to be boiled, heating is stopped after 10 min, and the the affected part is treated by the traditional Chinese medicine. The externally applied fumigation-washing traditional Chinese medicine can be used once a day for the patients with mild cases and be used twice a day for patients with severe cases. One bag can be used for 5 times, one course of treatment lasts for 15 days, and the effective rate of the sports injury and rheumatism type osteoarthropathy reaches up to 100% after 1-4 courses of treatment.
Of the total number of patients who received FORADIL AEROLIZER in adolescent and adult chronic dosing asthma clinical trials, 318 were 65 years of age or older and 39 were 75 years of age and older. Of the 811 patients who received FORADIL AEROLIZER in two pivotal multiple-dose controlled clinical studies in patients with COPD, 395 (48.7%) were 65 years of age or older while 62 (7.6%) were 75 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. A slightly higher frequency of chest infection was reported in the 39 asthma patients 75 years of age and older, although a causal relationship with FORADIL has not been established. Other reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out. (See PRECAUTIONS, Drug Interactions.)
The proposed evidence based protocol involves utilizing a single 30IU / 500mL bag of oxytocin. After the delivery of the anterior shoulder, an initial rapid infusion bolus of 50mL of the 30IU / 500mL at 999mL / hour. Three minutes after rapid infusion, uterine tone should be assessed. If inadequate uterine tone persists, a second rapid infusion at the same dose and rate as above should be given. If inadequate uterine tone persists, a third rapid infusion may be given. If adequate uterine tone is achieved after any rapid infusion, the remainder of the bag should be administered at a rate of 100mL / hour until finished. If adequate tone is not achieved, the remainder of the bag should be administered at 100mL / hour and additional uterotonic agents should be considered.
The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 treatment and the triglyceride glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients.
INTRODUCTION: Visual field defects (VFDs) represent a debilitating poststroke complication, characterized by unseen parts of the visual field. Visual perceptual learning (VPL), involving repetitive visual training in blind visual fields, may effectively restore visual field sensitivity in cortical blindness. This current multicenter, double-blind, randomized, controlled clinical trial investigated the efficacy and safety of VPL-based digital therapeutics (Nunap Vision [NV]) for treating poststroke VFDs.
METHODS: Stroke outpatients with VFDs (>6 months after stroke onset) were randomized into NV (defective field training) or Nunap Vision-Control (NV-C, central field training) groups. Both interventions provided visual perceptual training, consisting of orientation, rotation, and depth discrimination, through a virtual reality head-mounted display device 5 days a week for 12 weeks. The two groups received VFD assessments using Humphrey visual field (HVF) tests at baseline and 12-week follow-up. The final analysis included those completed the study (NV, n = 40; NV-C, n = 35). Efficacy measures included improved visual area (sensitivity ≥6 dB) and changes in the HVF scores during the 12-week period.
RESULTS: With a high compliance rate, NV and NV-C training improved the visual areas in the defective hemifield (>72 degrees2) and the whole field (>108 degrees2), which are clinically meaningful improvements despite no significant between-group differences. According to within-group analyses, mean total deviation scores in the defective hemifield improved after NV training (p = .03) but not after NV-C training (p = .12).
CONCLUSIONS: The current trial suggests that VPL-based digital therapeutics may induce clinically meaningful visual improvements in patients with poststroke VFDs. Yet, between-group differences in therapeutic efficacy were not found as NV-C training exhibited unexpected improvement comparable to NV training, possibly due to learning transfer effects.
Treatment sequence 2 will receive PF-06651600 every day for 11 days during the first period of the study (period 1) and a single dose of an oral contraceptive towards the end of this period. After completion of Period 1, there will be a washout period of at least 10 days before starting the second period of the study (period 2). During period 2, a single dose of an oral contraceptive will be received.
Glufosinate-ammonium (GLA), an organophosphate herbicide, is released at high concentrations in the environment, leading to concerns over its potential genotoxic effects. However, few articles are available in the literature reporting the possible cellular and nuclear effects of this compound. We assessed, by in vitro and in vivo micronucleus assays, the genotoxicity of GLA on cultured human lymphocytes and Lymnaea stagnalis hemocytes at six concentrations: 0.010 (the established acceptable daily intake value), 0.020, 0.050, 0.100, 0.200, and 0.500 µg/mL. In human lymphocytes, our results reveal a significant and concentration-dependent increase in micronuclei frequency at concentrations from 0.100 to 0.500 μg/mL, while in L. stagnalis hemocytes, significant differences were found at 0.200 and 0.500 μg/mL. A significant reduction in the proliferation index was observed at all tested concentrations, with the only exception of 0.010 μg/mL, indicating that the exposure to GLA could lead to increased cytotoxic effects. In L. stagnalis, a significant reduction in laid eggs and body growth was also observed at all concentrations. In conclusion, we provided evidence of the genomic and cellular damage induced by GLA on both cultured human lymphocytes and a model organism's hemocytes; in addition, we also demonstrated its effects on cell proliferation and reproductive health in L. stagnalis.
Atrial switch procedures such as the Mustard operation were previously popular for the complete transposition of the great arteries (i.e. dextro-transposition of the great arteries [d-TGA]). Patients with d-TGA who underwent atrial switch procedures approximately three decades ago have now entered adulthood. A female patient in her 30s with d-TGA had a paradoxical embolic stroke following the initiation of a low-dose oestrogen plus progesterone oral pill for dysmenorrhoea. She underwent Mustard surgery when she was 2 years old. Following a series of procedures including implantation of a permanent pacemaker that was required because of sinus node dysfunction, she had reached adulthood, was living by herself and working independently. One month after taking the low-dose oestrogen plus progesterone oral pill, venous thrombosis occurred in the left soleus and left peroneal veins; and she experienced an acute ischaemic stroke in the right middle cerebral artery area. Transoesophageal echocardiography revealed that the shunt was present only during the Valsalva manoeuvre. Based on the examinations, the patient was diagnosed with juvenile ischaemic stroke as a result of a paradoxical embolism. These findings suggest that paradoxical cerebral embolism can occur as a late complication in patients with d-TGA who underwent the Mustard operation as children.
First, to evaluate the feasibility of following each type of VLCD (high protein or high fat), participants will follow a standard carbohydrate diet for 2 weeks, followed by a 1 week transition to a VLCD, and then follow the a high protein VLCD for 2 weeks followed by a high fat VLCD for 2 weeks. The study will consist of 4 in person or virtual visits which will take place over \~7 weeks. All participants will be initially studied for 2 weeks while ingesting a standard diet recommended by the American Diabetes Association, followed by a 1-week transition to a VLCD, and followed by 2 weeks on each type of VLCD (high protein, high fat). During the first (baseline) period fasting β-hydroxybutyrate levels will be measured 2-3 times per week. During the VLCD study periods, fasting β-hydroxybutyrate levels will be measured daily in the morning using a blood ketone meter; insulin doses will be collected using insulin pump downloads and continuous glucose monitoring (CGM) profiles will be used to assess glycemic excursions on each diet, as well as the time in hypo-, eu- and hyperglycemic ranges. The purpose of this study is to examine changes in sensor glucose levels, basal and bolus insulin doses, and metabolic factors following implementation of a very low carbohydrate diet (VLCD). Sensor-derived time glucose ranges will serve as a surrogate marker of hemoglobin A1c given the short duration of the study. Safety measures of the diet will also be assessed, including daily fasting ketone levels.

The first hypothesis of the study is that use of a VLCD with strict monitoring of ketosis will reduce glycemic variability and increase time in target range, defined as 70-180 mg/dL by reducing the time in the hyperglycemic (\>180 mg/dL) and hypoglycemic ranges (\<70 mg/dL). Decreased carbohydrate intake will lead to less postprandial hyperglycemia. Lower insulin doses for meals and snacks as a result of decreased carbohydrate intake will lessen postprandial hypoglycemia as well.
A 3-dimensional structure comprising suitable cells (or entities) and the ECM (or matrix) that has been completely produced and arranged by these cells (or entities) that promotes the differentiation, dedifferentiation and/or transdifferentiation of cells and/or formation of tissue in vitro and in vivo, while at the same time promoting cell growth, proliferation, migration, acquisition of in vivo-like morphology, or combinations thereof, and that 1. provides structural and/or nutritional support to cells, tissue, organs, or combinations thereof, termed an "Autogenic Living Scaffold" (ALS); or 2. is capable of being transformed into a more complex tissue (or matrix) or a completely different type of tissue (or matrix), termed a "Living Tissue Matrix" (LTM). Autogenic means it is self-produced. The living cells that produce the LTM or ALS, or are added to Autogenic Living Scaffolds, may be genetically engineered or otherwise modified. The matrix component of the ALS or LTM provides a structural framework for cells that guide their direction of growth, enables them to be correctly spaced, prevents overcrowding, enables cells to communicate between each other, transmit subtle biological signals, receive signals from their environment, form bonds and contacts that are required for proper functioning of all cells within a unit such as a tissue, or combinations thereof. The ALS or LTM may thus provide proper or supporting mechanical and chemical environments, signals, or stimuli to other cells, to the cells that produce the ALS, to surrounding tissue at an implantation site, to a wound, for in vitro and ex vivo generation and regeneration of cells, tissue and organs, or combinations thereof. They may also provide other cells with nutrients, growth factors, and/or other necessary or useful components. They may also take in or serve as buffers for certain substances in the environment, and have also some potential at adapting to new environments.
PROBLEM TO BE SOLVED: To obtain a compsn. contg. a reducing agent which has stable curing time and adhesive strength even after storage for a long period of time, is less likely to cause discoloration of a cured product, and can provide a cured product suitable particularly for fixation of moving teeth. SOLUTION: This compsn. comprises an agent (A) comprising a polymerizable monomer, such as methyl methacrylate, contg. an acidic polymerizable monomer, such as 11-methacryloyloxy-1,1-undecanedicarboxylic acid, and a reducing agent; and an agent (B) comprising an org. peroxide, such as benzoyl peroxide. In this case, an arom. tertiary amine, such as N,N-dimethyl-p-toluidine, and an aliph. tertiary amine, such as dimethylaminoethyl acrylate or dimethylaminoethyl methacrylate, are used in combination as the reducing agent.
CRISPR-Cas9 has enabled a new generation of screening strategies to interrogate gene function. However, redundant genes and the complexity of functional gene networks can confound single gene knockout approaches. Furthermore, simple addition of two or more sgRNAs has shown only modest targeting efficacy in screening approaches. The present invention relates to combined orthogonal CRISPR-derived components to maximize gene targeting activity with minimal cross-talk and interference. The present invention also relates to efficient S. aureus Cas9 sgRNA design rules, which were paired with S. pyogenes Cas9 sgRNA design rules to achieve dual target gene inactivation in a high fraction of cells. Applicants developed a lentiviral vector and cloning strategy to generate high complexity pooled dual-knockout libraries and show that screening these libraries can identify combinatorial phenotypes, including synthetic lethal gene pairs across multiple cell types. The gene pairs can be targeted therapeutically and Applicants disclose therapeutically effective combination therapies.
Loteprednol Etabonate 0.2% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
We will consider for inclusion patients presenting in the emergency department with de novo acute hypoxemic respiratory failure (AHRF). De novo AHRF is defined as the requirement of oxygen flow rate of 5 liters per minute or more to maintain SpO2 of 90% or more in a patient who does not receive long term oxygen therapy.
Participants will receive daily text messages and all elements of standard care. They received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Key domains of message topics were chosen based on the content of evidence-based, relapse prevention treatment. Daily messages determined current level of functioning and provide intervention messages in response. Text messages will be sent via Google Voice on a research computer. Participants will respond to the text messages either with a specified response (e.g. YES/NO) or a generic response (e.g. "1"). Some messages will ask for a specific reply in response to a question. Based on the participant's response (e.g. "high," "med," "low"), the research assistant will respond with a text message tailored to the participant's message. All text messages will be sent to the HIC in an amendment to this protocol for approval.
BACKGROUND: Metagenomic next-generation sequencing (mNGS) has been increasingly applied in sepsis. We aimed to evaluate the diagnostic and therapeutic utility of mNGS of paired plasma and peritoneal drainage (PD) fluid samples in comparison to culture-based microbiological tests (CMTs) among critically ill patients with suspected acute intra-abdominal infections (IAIs).
METHODS: We conducted a prospective study from October 2021 to December 2022 enrolling septic patients with suspected IAIs (n = 111). Pairwise CMTs and mNGS of plasma and PD fluid were sent for pathogen detection. The mNGS group underwent therapeutic regimen adjustment based on mNGS results for better treatment. The microbial community structure, clinical features, antibiotic use and prognoses of the patients were analyzed.
RESULTS: Higher positivity rates were observed with mNGS versus CMTs for both PD fluid (90.0% vs. 48.3%, p < 0.005) and plasma (76.7% vs. 1.6%, p < 0.005). 90% of enrolled patients had clues of suspected pathogens combining mNGS and CMT methods. Gram-negative pathogens consist of most intra-abdominal pathogens, including a great variety of anaerobes represented by Bacteroides and Clostridium. Patients with matched plasma- and PD-mNGS results had higher mortality and sepsis severity. Reduced usage of carbapenem (30.0% vs. 49.4%, p < 0.05) and duration of anti-MRSA treatment (5.1 ± 3.3 vs. 7.0 ± 8.4 days, p < 0.05) was shown in the mNGS group in our study.
CONCLUSIONS: Pairwise plasma and PD fluid mNGS improves microbiological diagnosis compared to CMTs for acute IAI. Combining plasma and PD mNGS could predict poor prognosis. mNGS may enable optimize empirical antibiotic use.
FIELD: medicine, efferent therapy. SUBSTANCE: one should conduct preliminary volemic and anticoagulant preparation. Moreover, volemic one includes infusion of rheopolyglukin and Glugicir solution, and anticoagulant therapy deals with heparinization performed due to intravenous injection of heparin by drops to be conducted simultaneously with volemic preparation; plasmapheresis by continuous-flow method should be carried out in 20-30 min after volemic preparation, moreover, at carrying out plasmapheresis the ration of Glugicir:blood coming into blood separation device corresponds to 1: 3, the volume of removed plasma is compensated by equal volume of plasma- substituting solution; therapy course consists of 5 procedures at 3-5-dlong interval. The present innovation enables to obtain uricosuric effect, improve renal function and decrease blood level of uric acid. EFFECT: higher efficiency. 1 dwg, 1 ex